Among stroke survivors, the risk of developing dementia after stroke is significantly high, highlighting the need for targeted prevention strategies.

Deprescribing antihypertensive medication is not associated with the risk for hospitalization for myocardial infarction (MI) or stroke in long-term care residents, according to a study published ...

A boxed warning for testosterone on major adverse cardiovascular events is out and a new blood pressure warning is in, the ...

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

In recent years, the rate of cardiovascular mortality following high-risk myocardial infarction has significantly declined.

A clot-dissolving tissue plasminogen activator (tPA), tenecteplase is now indicated for acute ischemic stroke on top of its ...

Sotagliflozin, a dual SGLT1/2 inhibitor, reduces cardiovascular events in people with diabetic kidney disease — ischemic ...

In a trial, sotagliflozin use in patients with diabetes and chronic kidney disease (CKD) was associated with lower risk of ischemic cardiovascular outcomes.

The US Food and Drug Administration has approved Tenecteplase as first FDA-approved stroke medication in nearly three decades ...

For patients with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk factors, the dual sodium ...